ETF Trends covers a new exchange-traded fund from REX built around peptide drugmakers, aiming wider than the GLP-1 weight loss leaders.
Recap by typeshit. Full story at ETF Trends.
3:21
A short upload with no description, so the reasoning behind the claim isn't given. Worth a tap only if you follow the gray market retatrutide talk.
The dermatologist says many of her patients take GLP-1s, and calls her own weight loss on Zepbound, which she nicknames vitamin Z, life-changing.
A sponsored-style explainer that walks through semaglutide versus tirzepatide and the post-shortage compounding limits, while featuring telehealth company Mochi Health.
Drugs.com
Eligibility usually starts at a BMI of 30, or 27 with a weight-related condition. The piece also covers costs, side effects and why most people stay on these drugs long term.
Shoppers buying weight loss jabs or pills are being urged to compare providers, since prices vary widely between sellers. Only a short excerpt is available.
The protective effect showed up even at doses too low to cause meaningful weight loss, according to the Cedars-Sinai-led laboratory research.
Loading…